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ABSTRACT 
Active national pharmacovigilance programmes are needed to monitor adverse drug reaction (ADR) 
data in local populations. The objective of this study was to describe the knowledge, experiences, atti-
tudes and perceived barriers to reporting of suspected ADRs by community and hospital pharmacists in 
West Bank, Palestine. Between December 2014 and March 2015 we conducted a survey about the 
knowledge and attitude of pharmacists (n = 270) using a face-to-face questionnaire. The questionnaire 
consisted of questions about the sociodemographic characteristics of the pharmacists, their knowledge of 
pharmacovigilance and their attitudes towards ADR reporting. Main outcomes measured: The majority of 
the pharmacists (62.6%) worked in the community pharmacies and more females responded to the ques-
tionnaire than males (59% vs 41%). only 11.9% could conceptually or actually define 
‘pharmacovigilance’ correctly while one quarter of the respondent pharmacist (24.9%) could define ADR 
correctly. The hospital clinical pharmacists defined ‘pharmacovigilance’ correctly with higher signifi-
cance (P<0.001) when compared with community pharmacists. Only 12.2% had ever reported an ADR. 
The majority of these reports (85%) done by the hospital pharmacists (p<0.0001). The main reasons that 
discourage the pharmacists from reporting ADRs were ‘‘no enough information available from the patient 
(76.7%)’’, and ‘‘they did not know how to report (66.7%)’’. The majority of the respondents (92.0%) felt 
that reporting ADR was their duty and (82%) participants were interested in participating in the National 
Pharmacovigilance Programme in Palestine. The results show that Palestinian pharmacists have poor 
knowledge about pharmacovigilance. There is an urgent need for educational programs to train them 
about pharmacovigilance and ADR reporting scheme. 
Keywords: Pharmacovigilance, Adverse Drug Reaction, Reporting, Palestine. 
 
INTRODUCTION 
Adverse drug reactions (ADRs) are encoun-
tered commonly in daily practice, many of 
which are preventable (1, 2, 3). A study by 
Arulumani et al. indicates that 3.4% of the hos-
pital admissions may be attributed to ADRs. In 
addition, 3.7% of hospital patients developed 
ADRs during their hospital stay (4).  It is obvi-
ous that ADRs constitutes an economic burden 
on the health care system not to mention the ob-
vious morbidity and mortality associated with 
ADRs (5, 6). Thus, early detection and preven-
tion of ADR may be necessary. 
Traditionally, the role of the pharmacist was 
limited to the preparation and dispensing of 
drugs prescribed by the physician. Recently, the 
role of the pharmacist has expanded to other as-
pects of patient care (7, 8). These roles include 
reporting ADRs, improving patients’ health, and 
economic outcomes. Pharmacists can play an 
important role in ADR reporting and 
pharmacovigilance by increasing the number as 
well as the quality of submitted reports (9, 10). 
However, in many countries the knowledge of 
pharmacists about pharmacovigilance and ADR 
reporting is poor and the rate of reporting is low 
(11, 12, 13). 
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Till this published paper, there is no 
pharmacovigilance center in Palestine; however 
efforts from the Palestinian Ministry of Health 
and Pharmacist association are commence to 
establish a Palestinian pharmacovigilance center.  
In order to enhance the role of health profes-
sionals in spontaneous reporting in the near fu-
ture, it might be necessary to conduct an analysis 
of practice; attitude and knowledge of health 
care professional in order to design strategies 
that modify and enhance reporting. 
Evaluating the knowledge, behaviors and 
experiences of pharmacists relating to spontane-
ous reporting of ADRs is very important and 
lacking in Palestine. When pharmacists have 
sufficient knowledge of the ADR reporting pro-
cess, they can improve other healthcare profes-
sionals’ knowledge about ADR reporting (14). 
To the best of our knowledge no studies have 
evaluated pharmacists’ knowledge and attitudes 
toward ADRs reporting in the hospital and 
community settings in Palestine. Our study was 
in the unique position to assess their understand-
ing and knowledge about the Pharmacovigilance 
and spontaneous ADRs reporting scheme. 
Therefore the objective of this study was to de-
scribe the knowledge, experiences, attitudes and 
perceived barriers to reporting of suspected 
ADRs by community and hospital pharmacists 
in West Bank, Palestine. 
MATERIALS AND METHODS 
Study design, settings and study subjects 
This is a cross-sectional study that was con-
ducted in four of the largest cities in West Bank 
Palestine; Ramallah, Hebron, Bethlehem and 
Nablus. The study commenced in December 
2014 and continued for 3 months. Two hundred 
and seventy (270) pharmacists were included in 
the study with a response rate of 77.1%. Phar-
macists from all specialties working in hospitals, 
independent and chain pharmacies were enrolled 
in the study after obtaining an informed consent. 
Those who were not willing to participate or did 
not return the questionnaire within the stipulated 




The final form of the questionnaire consist-
ed of 25 questions was designed using the prec-
edence set by similar studies, (15-18) to obtain 
information regarding the demographics of the 
respondents, knowledge regarding the ADR re-
porting system, attitude and practice of ADR 
reporting, and the factors that encouraged and 
discouraged reporting. Content validity was as-
sessed by distributing the questionnaire to small 
randomly selected group of Palestinian pharma-
cists recruited to complete the validation pro-
cess. The initial draft of questionnaire was hand 
delivered to those pharmacists to help review the 
structured questionnaire and perform any 
amendments needed. 
Data collection and ethical consideration 
Well trained team consists of four pharma-
cist researchers visited each pharmacy and invit-
ed community and hospital pharmacists to par-
ticipate in the study after explaining the aims of 
the study. A written consent form was obtained 
from each participant who wished to participate 
in the study. Participants were told that all in-
formation provided was completely confidential 
and the results would be presented anonymous-
ly. 
Statistical Analysis 
Student’s t-test was used to compare con-
tinuous data. The x2 test was used to compare 
categorical data. All p-values presented are two-
tailed. P-Values<0.05 were considered statisti-
cally significant. The analyses were performed 
using SPSS version 19.0. 
RESULTS 
Demographics 
A total of 350 registered pharmacy practi-
tioners were approached. Only 270 responded to 
the survey with 270 pharmacists having all ques-
tions completely answered. The average re-
sponse rate was 77.1%. The demographics of the 
respondents are presented in Table 1. The mean 
age of the pharmacists was 32.9 (SD=6.5) years, 
with varying degree of education, 77% with 
Bachelor degree in Pharmacy, 11% with Master 
Degree; 4% with Pharm. D. and only 2% with 
Ph.D. More females responded to the question-
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naire than males (59% vs 41%). The majority of 
the pharmacists (62.6%) worked in the commu-
nity pharmacies and their experience in practice 
ranged from 1 to 26 years, the median years of 
experience were 6.8 years.  
Table (1): Demographic information for partici-
pated Pharmacists (n=270). 
Variables  Frequency (%)
Age (in years)  
20-29 143      (53.0)
30-39 99        (36.7)
>40 28        (10.4)
Mean (SD) 33.1      (5.8)
Gender  
Female 159      (58.9)
Male 111      (41.1)
Experience (in years)  
<5 61        (22.6)
5-10 136 (50.4) 
>10 73   (27.0) 
Degree of education  
Diploma 8     (2.9) 
Bachelor degree 213 (78.9) 
Master degree 27   (10.0) 
Pharm D degree 16   (6.0) 
PhD degree 6     (2.2) 
Employment status  
Community Pharmacy 169 (62.6)  
Hospital Pharmacy 79  (29.3) 
pharmaceutical industry 10   (3.7) 
sales and marketing 8     (2.9) 
Academic 4     (1.5) 
SD: Standard Deviation, Pham D: Doctor of 
Pharmacy. PhD: Doctor of Philosophy. 
Pharmacist counseling, knowledge regarding 
pharmacovigilance and ADR reporting 
Pharmacists were asked to define the terms 
‘pharmacovigilance’ and ‘adverse drug reac-
tion’. The open-ended questions were evaluated 
according to the WHO’s definition. 
Of the responding pharmacists, only 11.9% 
could conceptually or actually define 
‘pharmacovigilance’ correctly while one quarter 
of the respondent pharmacist (24.9%) could de-
fine ADR correctly. The hospital clinical phar-
macists defined ‘pharmacovigilance’ correctly 
with higher significance (P<0.001) when com-
pared with community pharmacists. Significant 
difference was also found between the Pharm D 
Pharmacists and Bachelor degree pharmacist 
(P<0.001) for the definition of ADR. Only 23 
(22%) of the participants said that they were fa-
miliar with the ADR reporting process. The re-
sponses to knowledge items are illustrated in 
Table 2; about half of the pharmacists only ever 
discuss ADR with the patients, prescribers or 
colleagues. Very few (11.2%) of the participants 
said they reported ADRs when they occurred 
and most of those from hospital pharmacists 
(p<0.0001). The main reasons for not reporting 
ADRs; (71.5%) said that they were not aware of 
the method of reporting, (11.6%) said that ADR 
reporting was the duty of physicians and hospital 
pharmacists, and 4 (8.3%) said that  all ADRs 
are familiar and already reported in the medica-
tion leaflet.  
Table (2): Patient counseling about ADR, n(%) for 270 respondents. 
Questions Never Rarely Sometimes Frequently Always 
How often do you ask your patient if 
he/she is allergic to medications?  
0  24 (8.8) 81 (30.0) 65 (24.1) 100 (37.0) 
How often do you ask a female if she 
is pregnant when dispensing 
teratogenic/ abortive medication? 
0 11 (4.1) 43 (15.9) 81 (30.0) 135(50.0) 
How often do you counsel your pa-
tients about ADRs that they may expe-
rience from their medication? 
3 (1.1) 24 (8.8) 52 (19.3) 78 (28.9) 113 (41.9)
How often do you discuss an ADR 
with your pharmacist colleague? 
13(4.8) 24 (8.8) 54 (20.0) 75 (27.8) 104 (38.5)
How often do you discuss an ADR 
with the prescriber? 
27 (10.0) 83 (30.7) 68 (25.2) 41 (15.2) 51 (18.9)
ADR: Adverse Drug Reaction  
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Experience of ADR reporting  
The experience and practice of ADRs re-
porting by pharmacists is shown in Table 3. It is 
obvious that about (245, 90.7%) of the pharma-
cists had noticed at least one ADR in a patient 
per a year, while only (33, 12.2%) had ever re- 
ported an ADR. The majority of these reports 
(85%) done by the hospital pharmacists 
(p<0.0001). Reporters mostly submitted their 
documentation to their hospitals, but also some 
submitted directly to the drug manufacturer.  
Table (3): Pharmacists Practice toward ADRs reporting procedure. 
Questions  Number % 
How often do the patients report you ADRs of medications?  
More than once a week 62 23.0 
Once a month 83 30.7 
A few times a year 100 37.0 
Never 25 09.3 
Have you ever reported any ADR??  
Yes  33 12.2 
No 237 87.8 
Do you know what is the period within which you should report a 
serious ADR experienced by a patient?
 
Yes 14 5.2 
No 256 94.8 
Do you know to whom you should report the ADRs?  
The Ministry of health (MOH) 87 32.2 
The pharmaceutical association 25 9.3 
Drug Company 127 47.0 
Prescriber 27 10.0 
Others 4 1.50 
How do you prefer to report the ADRs?  
A phone call to drug company 70 25.9 
The representative of the drug company 57 21.1 
Using adverse drug reaction reporting form 102 37.8 
Mail via internet 35 13.0 
Others  6 2.2 
ADRs: Adverse Drug Reactions. 
Pharmacists were also asked about their pre-
ferred method of reporting ADR, 37.8% of them 
believed that using a specific form was their pre-
ferred method of reporting, while 25.9%, 21.1%, 
and 13.0% preferred to report via phone calls to 
the drug company, informing the representative 
of the drug company verbally or by using inter-
net, respectively 
Pharmacists Attitudes toward 
Pharmacovigilance and ADR reporting pro-
cess 
There were 7 questions related to the per-
ceptions of the pharmacists towards ADR re-
porting and pharmacovigilance. In general, the 
respondents had a positive attitude towards ADR 
reporting and pharmacovigilance. The majority 
of the respondents (92.0%) believed that we 
need a pharmacovigilance centre in this country 
and (87%) felt that reporting ADR was their du-
ty. n (82%) participants were interested in par-
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ticipating in the National Pharmacovigilance 
Programme in Palestine. However, the majority 
felt that they weren’t adequately trained in ADR 
reporting process. The details regarding the re-
sponses of pharmacists about their attitudes to-
wards ADR reporting and pharmacovigilance 
are listed in Table 4. 
Table (4): Pharmacists’ attitudes towards the reporting of suspected ADR’s (n=270). 
Questions Yes No Not Sure 
Do you believe that we need a 
pharmacovigilance centre in this country  248 (91.9)  13 (4.8) 9 (3.3) 
Do you think reporting ADR is a pharmacist’s 
duty? 221 (81.9) 24 (8.9) 25 (9.3) 
Do you believe reporting ADRs will improve 
patient safety? 256 (94.8) 11 (4.1) 3 (1.1) 
Are you interested in participating in the ADRs 
reporting system? 221 (81.9) 32 (11.9) 17 (6.3) 
Reporting ADRs causes inconvenience in the 
working place 24 (8.9) 218 (80.7) 28 (10.4) 
Do you feel that you are adequately trained in 
ADR reporting? 32 (11.9) 229 (84.8) 9 (3.3) 
Does your workplace encourage you to report 
an ADR? 221 (81.9) 32 (11.9) 17 (6.3) 
ADRs: Adverse Drug Reactions 
Factors influencing the pharmacists to re-
port ADRs were evaluated in this study.  Most 
of pharmacist indicated that they report reactions 
of serious nature, unusual reactions, and reac-
tions that have been not reported before. Factors 
that may discourage the pharmacists to report 
ADRs were also illustrated in table 5. The main 
reasons that discourage the pharmacists from 
reporting ADRs were ‘‘no enough information 
available from the patient (76.7%)’’, ‘‘they did 
not know how to report (66.7%)’’ and ‘‘The 
ADR is too trivial to report (67.1%).  
Table (5): Factors that may discourage pharmacists to report ADRs. 
Item Agree  Disagree Not Sure 
Uncertain association between the drug and the adverse 
reaction 153 (56.7) 86 (31.9) 31 (11.5) 
The ADR is too trivial to report 183 (67.8) 68 (25.2) 19 (7.0) 
Concern that a report will generate extra work 89 (33.0) 148 (54.8) 33 (12.2) 
Lack of confidence in discussing the ADRs with the pre-
scriber 137 (50.7) 113 (41.9) 20 (7.4) 
No enough information available from the patient 197 (73.0) 59 (21.9) 14 (5.2) 
Lack of time to fill in a report 116 (43.0) 132 (48.9) 22 (8.1) 
Fear of legal liability / Fear of facing legal problems 121 (44.8) 118 (43.7) 31 (11.5) 
Consider it the doctors’ responsibility 35 (13.0) 213 (78.9) 22 (8.1) 
Did not know how to report 191 (70.7) 54 (20.0) 25 (9.3) 
ADRs: Adverse Drug Reactions. 
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DISCUSSION 
According to our knowledge, this is the first 
study from West Bank, Palestine which evalu-
ates the Knowledge, practice and attitudes of the 
pharmacists towards pharmacovigilance. The 
present study firstly demonstrates that the major-
ity of the pharmacists in West Bank have insuf-
ficient knowledge about pharmacovigilance and 
ADRs reporting process. There are several re-
ports from other countries which commonly em-
phasize the problem of the ADR under-reporting 
among pharmacists (19-22). 
Despite the lack of knowledge in the ma-
jority of pharmacists, the present study revealed 
that hospital pharmacists was better knowledge-
able compared to community pharmacists in 
ADR reporting procedures. This may be at-
tributed to the fact that hospital pharmacists are 
in direct contact with other health care profes-
sionals such as physicians and nurses who are 
more often involved in the identification of po-
tential ADRs, thus they are more exposed to sit-
uations where there is a need to manage or to 
report such adverse effects. 
Previous study showed that hospital phar-
macists report 20 times more frequently than 
community pharmacists, this was due to the fact 
that the hospital pharmacist was better educated 
and informed about pharmacovigilance practice 
(19). 
About half of the pharmacists 47% in this 
study believed that if they want to report ADRs 
they will send their report to drug Company or 
their representatives; this revealed the need for 
authorized organization for reporting ADR in 
Palestine.  
Spontaneous reporting programs are the 
most widely reporting programs operate on the 
basis that all ADRs should be reported despite 
uncertainty about a causal relationship. Even in 
the developed countries where the 
pharmacovigilance programs are well-
established, a high level of under‑reporting is 
documented (23-25). The majority of study par-
ticipants believed of the importance of the pres-
ence of pharmacovigilance center in this country 
and considered ADRs reporting to be a natural 
task for pharmacists, as well as main responsi-
bility of all healthcare providers, however ADRs 
reporting is extremely low regardless these posi-
tive attitudes, similar to other studies (20, 26). 
However Pharmacist can play a major role in 
preventing ADRs reporting. In the developing 
countries, patients prefer to contact pharmacists 
first for any consultation regarding their medica-
tions because they easily accessed healthcare 
providers. Therefore, pharmacists need to take a 
more active role in the assessment and decision 
making concerning the safety of patient medica-
tions. 
In the present study it was noted that also 
hospital pharmacists have insufficient 
knowledge of pharmacovigilance practices and 
reporting process. The main reasons for un-
derreporting of ADRs are no enough infor-
mation available from the patient, they did not 
know how to report and the ADR is too trivial to 
report. These findings were similar to results of 
a study performed on pharmacists in other coun-
tries (27-29). Pharmacists and other healthcare 
providers should consider ADRs reporting as an 
obligation at their working places and ADRs 
reporting systems in hospitals should be a priori-
ty basis for the success of the pharmacovigilance 
programs and the better clinical management of 
the patients. 
Previous studies have demonstrated that 
knowledge and attitudes play an important role 
on ADR reporting (19). Furthermore, attitudes 
may be modifiable variables. Granas et al. (20) 
have shown that pharmacists’ reporting-related 
attitudes can be significantly modified in a posi-
tive manner following educational programs that 
influence the ADR reporting.  Developing a 
written hospital policy, better cooperation with 
clinicians, training, simplifying the system, allo-
cation of time for ADR reporting, publicity and 
Promotion will improve the ADR reporting 
among Pharmacists and other healthcare profes-
sionals. In this country further studies needed to 
evaluate the influence of the education and train-
ing programs on the ADR reporting behaviors.  
The main limitations of this study that the 
study findings could not be generalized to all 
community and hospital pharmacists as more 
Khdour, et al. ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  47 
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national studies needed. Also we are aware of 
some methodological weaknesses of our study; 
as the questionnaire relied on pharmacists’ self-
rated assessment of their own practice and atti-
tudes, pharmacists might have been unwilling to 
reveal their practice deficiencies.  
CONCLUSIONS 
The results show that Palestinian pharma-
cists have poor knowledge about 
pharmacovigilance. There is an urgent need for 
educational programs to train them about 
pharmacovigilance and ADR reporting scheme. 
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